Stromatt Scott C 4
4 · Aptevo Therapeutics Inc. · Filed Mar 4, 2019
Insider Transaction Report
Form 4
Stromatt Scott C
Chief Medical Officer and SVP
Transactions
- Exercise/Conversion
Restricted Stock Unit
2019-03-01−16,269→ 0 total→ Common Stock (16,269 underlying) - Award
Stock Option (right to buy)
2019-02-28+67,400→ 67,400 totalExercise: $1.52Exp: 2029-02-28→ Common Stock (67,400 underlying) - Exercise/Conversion
Common Stock
2019-03-01+16,269→ 221,006 total - Tax Payment
Common Stock
2019-03-01$1.57/sh−4,823$7,572→ 216,183 total
Footnotes (3)
- [F1]Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis.
- [F2]The option vests in three approximately equal annual installments beginning on February 28, 2020.
- [F3]The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vested in three equal annual installments beginning on the anniversary of the grant date.